Market Research Logo
Region: Africa
Category: Country Overviews

Africa Country Overviews

(76 reports matching your criteria)
  • Ghana Pharmaceuticals & Healthcare Q2 2018

    ... over innovative multinational firms. In order to ensure thepopulation’s healthcare and access to safe medicines are not compromised by such measures, protectionist policies aimed atboosting local drugmaker capabilities must be accompanied by improvements to medical ... Read More

  • Tunisia Pharmaceuticals & Healthcare Q2 2018

    ... with domesticfirms. Improving healthcare access will be beneficial to the country's pharmaceutical market growth prospects over the comingyears; however, growth will remain limited by the steady uptake of generic drugs in the country. The next ... Read More

  • Gabon Pharmaceuticals & Healthcare Q2 2018

    ... signal greater commercial potential fordrugmakers, however, exploiting these opportunities will be challenging in nature as the undeveloped status of the country'spharmaceutical and healthcare markets poses a much less receptive environment for drugmaker opportunities in Sub-SaharanAfrica. Read More

  • Mozambique Pharmaceuticals & Healthcare Q2 2018

    ... significantly low as a result of widespread poverty amongst the population, limiting potential revenue prospects for drugmakers.Furthermore, weak intellectual property standards and a poorly enforced pricing regime make Mozambique a high-risk environmentfor innovative medicine producers. Read More

  • Namibia Pharmaceuticals & Healthcare Q2 2018

    ... country's competitiveness in theSouthern Africa region. These factors continue to act as a deterrent to multinational pharmaceutical company investment in thelocal production of medicines. As a result, Namibia is heavily reliant on importing the majority ... Read More

  • Botswana Pharmaceuticals & Healthcare Q2 2018

    ... diversify the country’s economyand invests in infrastructure. However, although Botswana makes for a relatively attractive manufacturing destination, its smallmarket size will continue to limit foreign drugmaker interest as they instead opt for South Africa as ... Read More

  • Tanzania Pharmaceuticals & Healthcare Report Q2 2018

    ... over the coming years. However, we note that growth will bepartly due to inflationary pressures from a relatively low value base. The demand for high-value drugs will remain limited by itsunderdeveloped healthcare system and low ... Read More

  • Cameroon Pharmaceuticals & Healthcare Report Q2 2018

    ... implementation phase reach a high level ofsuccess, the UHC scheme has the potential to transform Cameroon's health system while positioning the country among the mostpromising in Sub-Saharan Africa in terms of health sector growth. We ... Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Report Q2 2018

    ... urbanization, the region's overwhelming chronic disease burdenwill be an important factor supporting pharmaceutical and healthcare market growth over a multi-year horizon. There is a significantdisparity between different countries' healthcare systems in the MENA region, resulting ... Read More

  • Uganda Pharmaceuticals & Healthcare Report Q2 2018

    ... access tothese essential medicines. While the government recognises the need to improve the situation and is implementing certainstrategies to address this, health sector inefficiencies persist and there is an absence of a sustainable, long-term plan. Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Report Q2 2018

    ... of healthcare coverage deter any meaningful investment bymultinational firms. While a positive economic trajectory bodes well for government finances, the focus will remain on the deliveryof basic healthcare services, offering limited opportunities for foreign pharmaceutical ... Read More

  • Morocco Pharmaceuticals & Healthcare Report Q2 2018

    ... improving healthcare quality and coverage. However, innovative drugmakers willremain deterred by the relatively small scale of the market as well as the low purchasing power of the population. Further downsiderisks include the government's increasing preference ... Read More

  • Nigeria Pharmaceuticals & Healthcare Report Q2 2018

    ... The majority of multinational players will continue to optfor an indirect presence as the business climate remains decidedly difficult, yet the long-term opportunities will manifest in line witheconomic growth and greater investor sentiment. While opportunities ... Read More

  • Zambia Pharmaceuticals & Healthcare Report Q2 2018

    ... a poor incentive for multinational involvement, especially given patchy healthcare infrastructure and low per capitapurchasing power. Local pharmaceutical demand is presently mostly met by imports and donations, although some direct foreigninvestment has featured of late. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q2 2018

    ... - a headwind to drugmaker and private sectoropportunities in Ethiopia. The Ethiopian Pharmaceutical Manufacturing Sector Strategy and Action Plan highlights the government'spolitical will to improve policy coherence in the sector, while trying to improve the ... Read More

  • Sudan and South Sudan Pharmaceuticals & Healthcare Report Q2 2018

    ... relations with the US, the operating environment remains highlychallenging and will continue to restrict company activity. Over the long term, a gradually improving business climate and Sudan'smore favourable position in the International community hold upside ... Read More

  • Algeria Pharmaceuticals & Healthcare Q2 2018

    ... the health sector and the pharmaceutical industry will likely benefit the ongoing development of drug manufacturing capacity as well as health system management. Given rising healthcare costs and fiscal consolidation efforts, however, the government will ... Read More

  • Angola Pharmaceuticals & Healthcare Q2 2018

    ... Opportunities exist for manufacturers willing to invest in a small yet unexploited market, yet the difficult operating environment and lack of clear regulation will ensure that generic drugmakers dominate the competitive landscape - the majority ... Read More

  • Kenya Pharmaceuticals & Healthcare Q2 2018

    ... over the longer term, we expect the country's high chronic and communicable disease burden and the generally open economy to continue to attract multinational players. On the downside, per-capita spending on medicines and health services ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q1 2018

    ... This indicates a low demand for high-value pharmaceutical products and with poor access to medicine, due to an underdeveloped healthcare infrastructure, we expect patented drugs sales to remain almost non-existent over the forecast. We expect ... Read More

  • Uganda Pharmaceuticals & Healthcare Q1 2018

    ... with opportunities being presented for multinationals selling high-value patented drugs. On the other hand, Uganda's public healthcare sector will remain underfunded, and hence underdeveloped, with the private sector remaining the largest in terms of value. Read More

  • Healthcare Infrastructure in Nigeria, Key Opportunities 2017–2020

    ... growth of around 7% for the past decade is threatened by macroeconomic challenges, particularly exchange-rate volatility and falling global oil prices that impact public-sector spending. Nigeria is the most populated country in the African continent ... Read More

  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Egypt

    ... 1990s, the pharmaceutical industry was dominated by state-owned companies, but the overall scenario changed following economic liberalization, when the private sector took the highest share of production in the domestic market (GAFI, 2017a). Egypt Pharmaceutical ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q1 2018

    ... local medicine demand. We expect that domestic drugmakers' performance will improve in line with increasing government support, although the benefits are unlikely to be realised over the near-term. The majority of multinational drugmakers will continue ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q1 2018

    ... significant underlying burden of infectious diseases, the burden of non-communicable diseases will continue to increase at a faster rate due to the growing middle class and resulting lifestyle changes, providing improved revenue-earning opportunities for drugmakers ... Read More

< prev 1 3 4